Welcome to our dedicated page for Chimerix news (Ticker: CMRX), a resource for investors and traders seeking the latest updates and insights on Chimerix stock.
News about Chimerix, Inc. (NASDAQ: CMRX) centers on its work as a biopharmaceutical company developing medicines for patients facing deadly diseases, with a particular focus on rare and high-grade brain tumors. Recent press releases emphasize the company’s lead clinical program, dordaviprone (ONC201), in development for H3 K27M-mutant diffuse glioma.
Investors and followers of CMRX news will find updates on key regulatory milestones, including the U.S. Food and Drug Administration’s acceptance of Chimerix’s New Drug Application for dordaviprone in recurrent H3 K27M-mutant diffuse glioma, Priority Review status, and the assigned PDUFA target action date of August 18, 2025. Company news also highlights Rare Pediatric Disease Designation, Fast-Track Designation, and Orphan Drug Designation for dordaviprone in multiple regions.
Chimerix news releases describe ongoing clinical development activities, such as the Phase 3 ACTION trial in newly diagnosed, non-recurrent H3 K27M-mutant diffuse glioma patients following radiation, and Phase 1 dose escalation studies of ONC206 to evaluate safety and pharmacokinetic data. Additional items include corporate events like participation in oncology and precision medicine forums and updates on equity inducement grants under Nasdaq Listing Rule 5635(c)(4).
Another major theme in recent CMRX coverage is the definitive agreement for Jazz Pharmaceuticals to acquire Chimerix for approximately $935 million in cash. News articles outline the transaction terms, expected closing timing subject to customary conditions, and how dordaviprone would fit within Jazz’s rare oncology portfolio. For readers tracking CMRX, this news stream provides a view into Chimerix’s clinical progress, regulatory interactions, and announced strategic transaction with Jazz.
Chimerix (NASDAQ: CMRX), a biopharmaceutical firm, announced its participation in two investor conferences in September. The events include the H.C. Wainwright 22nd Annual Global Investment Conference on September 14 at 1:00 p.m. ET, where Chimerix will present a corporate overview and hold investor meetings. Additionally, management will engage in investor meetings at the Cantor Fitzgerald Virtual Healthcare Conference on September 16. A live audio webcast of the presentation will be available on their Investor Relations website.
Chimerix focuses on developing innovative treatments, including DSTAT for acute lung injury and BCV as a countermeasure for smallpox.
Chimerix (NASDAQ: CMRX) will host a live conference call and audio webcast on August 10, 2020, at 8:30 a.m. ET, to discuss its second-quarter financial results ending June 30, 2020, and provide a business overview. The call can be accessed by dialing (877) 354-4056 (domestic) or (678) 809-1043 (international). Chimerix focuses on developing innovative medicines for cancer and serious diseases, with clinical-stage programs including dociparstat sodium (DSTAT) for acute lung injury related to COVID-19 and brincidofovir (BCV) for smallpox.
Chimerix (NASDAQ: CMRX) appointed Dr. Allen Melemed as Chief Medical Officer, aiming to leverage his extensive experience in oncology. His role is crucial as Chimerix prepares for a Phase 3 trial for dociparstat sodium (DSTAT) in acute myeloid leukemia (AML) and a Phase 2/3 trial for COVID-19 acute lung injury. DSTAT shows promise in improving survival rates in AML patients and managing inflammation in COVID-19. Dr. Melemed has over 20 years of experience in clinical development at Eli Lilly, contributing to significant oncology drugs.
Chimerix (NASDAQ: CMRX) announced that CEO Mike Sherman will present a corporate overview at the Jefferies Virtual Healthcare Conference on June 4, 2020, at 9:30 a.m. ET. The presentation will be available live on the Investor Relations section of their website and archived for 90 days. Chimerix is focused on developing innovative medicines for serious diseases, with ongoing clinical programs for dociparstat sodium (DSTAT), aimed at treating COVID-19, and brincidofovir (BCV) for smallpox. DSTAT is undergoing a Phase 2/3 trial to assess its efficacy in patients with severe COVID-19.
Summary not available.